Novartis AG - Depositary Receipt (Common Stock)
US ˙ NYSE ˙ US66987V1098

SecurityNVS / Novartis AG - Depositary Receipt (Common Stock)
InstitutionWiley Bros.-aintree Capital, Llc
Latest Disclosed Ownership142,824 shares
Latest Disclosed Value $ 21,817,102
Wiley Bros.-aintree Capital, Llc reports 7.17% increase in ownership of NVS / Novartis AG - Depositary Receipt (Common Stock)

On May 15, 2026 - Wiley Bros.-aintree Capital, Llc filed a 13F-HR form disclosing ownership of 142,824 shares of Novartis AG - Depositary Receipt (Common Stock) (US:NVS) valued at $21,816,366 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 133,267 shares of Novartis AG - Depositary Receipt (Common Stock). This represents a change in shares of 7.17% during the quarter. The current value of the position is $21,303,628 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F NOVARTIS SPONSORED ADR 66987V109 142,824 9,557 7.17 21,817 18.74 0.1078
2026-02-17 2025-12-31 13F NOVARTIS SPONSORED ADR 66987V109 133,267 16,550 14.18 18,374 22.05 0.0961
2025-11-14 2025-09-30 13F NOVARTIS SPONSORED ADR 66987V109 116,717 10,081 9.45 15,054 16.42 0.0964
2025-08-14 2025-06-30 13F NOVARTIS SPONSORED ADR 66987V109 106,636 9,588 9.88 12,932 17.98 0.0992
2025-05-15 2025-03-31 13F NOVARTIS SPONSORED ADR 66987V109 97,048 5,968 6.55 10,960 23.23 0.1164
2025-02-14 2024-12-31 13F NOVARTIS SPONSORED ADR 66987V109 91,080 61,887 211.99 8,894 164.39 0.1067
2024-11-14 2024-09-30 13F NOVARTIS SPONSORED ADR 66987V109 29,193 11,833 68.16 3,364 82.03 0.0649
2024-07-24 2024-06-30 13F NOVARTIS SPONSORED ADR 66987V109 17,360 6,438 58.95 1,848 74.18 0.0809
2024-04-11 2024-03-31 13F NOVARTIS SPONSORED ADR 66987V109 10,922 4,943 82.67 1,062 72.80 0.1463
2024-01-09 2023-12-31 13F NOVARTIS SPONSORED ADR 66987V109 5,979 5,979 615 0.1497
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.